Abstract 1114
Infants enrolled in the trial, Early Inhaled Glucocorticoid Therapy for Prevention of BPD, were assessed at 6±2 months corrected age (CA) for growth, rehospitalization, medications, and pulmonary function. Beclomethasone therapy was associated with less systemic steroid and bronchodilator therapy, but did not prevent BPD (Pediatr Res. 1998;43:278A). Histories and physical examinations were conducted at 3 study sites, and pulmonary function at 2 sites. Non-paired t tests were used for continuous variables, Wilcoxon rank sum tests for data not normally distributed, and chi square tests for categorical variables.
Results: Of 253 enrolled infants, 153 were evaluated; 116 of 153 infants (66 placebo; 50 beclomethasone) were assessed at 6±2 months CA. Groups were similar in growth, diuretic and bronchodilator therapy, and rehospitalizations. Among 86 infants with pulmonary function studies, 52 were assessed at 6±2 months CA. Groups were similar in O2 saturations at FiO2 21% and 17% over 6 minutes, and in pulmonary mechanics (minute ventilation, tidal volume, dynamic compliance, total pulmonary and expiratory resistance, FRC, FEV at 75%, 50%, and FEFmax at FRC, I and E time).
Conclusion: This regimen of early beclomethasone therapy was associated with no difference between groups in growth, rehospitalizations, medications, or pulmonary function at 6±2 months CA. Greater systemic steroid therapy in the placebo group may have masked differences between groups.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cole, C., Abbassi, S., Dorkin, H. et al. Early Inhaled Glucocorticoid Therapy for Prevention of BPD: Assessment of Growth, History, and Pulmonary Function at 6 Months Corrected Age. Pediatr Res 45, 190 (1999). https://doi.org/10.1203/00006450-199904020-01131
Issue Date:
DOI: https://doi.org/10.1203/00006450-199904020-01131